PetMed Express (NASDAQ:PETS – Get Rating) announced its quarterly earnings data on Monday. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.03, MarketWatch Earnings reports. PetMed Express had a net margin of 7.83% and a return on equity of 16.00%. During the same period last year, the company earned $0.34 EPS.
Shares of PETS stock opened at $20.81 on Tuesday. The firm has a fifty day moving average of $25.39 and a 200-day moving average of $26.24. PetMed Express has a 12-month low of $19.65 and a 12-month high of $46.67. The company has a market capitalization of $436.57 million, a price-to-earnings ratio of 19.27 and a beta of 0.55.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 27th. Stockholders of record on Friday, May 20th will be given a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 5.77%. PetMed Express’s dividend payout ratio is 111.11%.
Several hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its position in shares of PetMed Express by 6.7% during the fourth quarter. BlackRock Inc. now owns 3,290,803 shares of the company’s stock worth $83,125,000 after acquiring an additional 205,445 shares in the last quarter. State Street Corp grew its position in PetMed Express by 2.3% in the fourth quarter. State Street Corp now owns 1,022,162 shares of the company’s stock valued at $25,820,000 after purchasing an additional 22,763 shares in the last quarter. Allianz Asset Management GmbH grew its position in PetMed Express by 30.4% in the fourth quarter. Allianz Asset Management GmbH now owns 496,199 shares of the company’s stock valued at $12,534,000 after purchasing an additional 115,569 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in PetMed Express by 10.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 437,790 shares of the company’s stock valued at $11,059,000 after purchasing an additional 43,173 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in PetMed Express by 2.0% in the third quarter. Bank of New York Mellon Corp now owns 372,529 shares of the company’s stock valued at $10,009,000 after purchasing an additional 7,378 shares in the last quarter. 80.95% of the stock is owned by institutional investors.
About PetMed Express (Get Rating)
PetMed Express, Inc, together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
- Get a free copy of the StockNews.com research report on PetMed Express (PETS)
- Intuitive Surgical is an Intuitive Buy
- The Low In Lordstown Motors May Not Be The Last
- Follow The Money To Cigna
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
- Johnson Outdoors Falls On Bleak Outlook
Receive News & Ratings for PetMed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express and related companies with MarketBeat.com's FREE daily email newsletter.